Complete release of vitreous adhesion · people with symptomatic vitreomacular adhesion
Ocriplasmin injection leads to higher complete release of vitreous adhesion compared with control (high certainty).
1 finding from 1 review
RR 3.46 [2, 6]
Studies not reported
High
Closure of macular hole · people with symptomatic vitreomacular adhesion
Ocriplasmin injection leads to higher closure of macular hole compared with control (high certainty).
1 finding from 1 review
RR 2.87 [1.5, 5.51]
Studies not reported
High
Complete posterior vitreous detachment · people with symptomatic vitreomacular adhesion
Ocriplasmin injection leads to higher complete posterior vitreous detachment compared with control (high certainty).
1 finding from 1 review
RR 2.94 [1.39, 6.24]
Studies not reported
High
3‐line or greater improvement in best‐corrected visual acuity · people with symptomatic vitreomacular adhesion
Ocriplasmin injection probably leads to higher 3‐line or greater improvement in best‐corrected visual acuity compared with control (moderate certainty).
1 finding from 1 review
RR 1.95 [1.07, 3.53]
Studies not reported
Moderate
Requirement for vitrectomy · people with symptomatic vitreomacular adhesion
Ocriplasmin injection probably leads to lower requirement for vitrectomy compared with control (moderate certainty).
1 finding from 1 review
RR 0.67 [0.5, 0.91]
Studies not reported
Moderate
Mean change in validated visual function questionnaire score from baseline Score ranges from 0 to 100, higher scores are better visual function · people with symptomatic vitreomacular adhesion
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Adverse events (ocular problems) · people with symptomatic vitreomacular adhesion
Ocriplasmin injection probably leads to higher any ocular adverse event compared with control (moderate certainty).
1 finding from 1 review
RR 1.22 [1.09, 1.37]
Studies not reported
Moderate
Number of injections at 1 year · people with neovascular age‐related macular degeneration
1 finding from 1 review
Number of injections at 1 year · people with neovascular age‐related macular degeneration
1 finding from 1 review
Visual acuity · macular edema in diabetes
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Gain of 3 or more lines of visual acuity · macular edema in diabetes
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes gain of three or more lines visual acuity ‐ 24 months** compared with sham (very low certainty).
1 finding from 1 review
RR 4.12 [0.48, 34.99]
Studies not reported
Very low
Change in retinal thickness (micron) (negative is better) · macular edema in diabetes
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Cataract progression ‐ 24 months · macular edema in diabetes
Intravitreal triamcinolone acetonide injection 4 mg showed no clear difference in cataract progression ‐ 24 months compared with sham (low certainty).
1 finding from 1 review
RR 3 [0.97, 9.3]
Studies not reported
Low
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes use of IOP‐lowering medications ‐ 24 months compared with sham (very low certainty).
1 finding from 1 review
RR 21.6 [1.32, 354.7]
Studies not reported
Very low
Surgery for glaucoma ‐ 24 months · macular edema in diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes change in visual acuity (logMAR) ‐ 12 months (negative is better) compared with macular laser (very low certainty).
1 finding from 1 review
MD 0.02
Studies not reported
Very low
Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes
Intravitreal triamcinolone acetonide injection 4 mg showed no clear difference in gain of three or more lines visual acuity ‐ 12 months compared with macular laser (low certainty).
1 finding from 1 review
RR 0.85 [0.55, 1.3]
Studies not reported
Low
Change in retinal thickness (micron) (negative is better) · macular edema in diabetes
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes change in retinal thickness (micron) (negative is better) compared with macular laser (very low certainty).
1 finding from 1 review
MD 5
Studies not reported
Very low
Cataract progression · macular edema in diabetes
Intravitreal triamcinolone acetonide injection 4 mg probably leads to higher cataract progression ‐ 9 to 24 months compared with macular laser (moderate certainty).
1 finding from 1 review
RR 2.68 [2.21, 3.24]
Studies not reported
Moderate
Use of IOP‐lowering medications · macular edema in diabetes
Intravitreal triamcinolone acetonide injection 4 mg probably leads to higher use of IOP‐lowering medications ‐ 9 to 24 months compared with macular laser (moderate certainty).
1 finding from 1 review
RR 3.92 [2.59, 5.96]
Studies not reported
Moderate